Dementia with Lewy Bodies Biomarkers

Pathway Diagram

Introduction

Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer's disease, accounting for approximately 10-15% of all dementia cases [1][2]. DLB is characterized by the presence of Lewy bodies (intracellular inclusions composed of misfolded alpha-synuclein protein) and Lewy neurites throughout the brain [3]. The clinical phenotype includes progressive cognitive decline with prominent fluctuations, visual hallucinations, and parkinsonism, along with autonomic dysfunction and sleep disturbances [4][5].

Pathway Diagram

Introduction

Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer's disease, accounting for approximately 10-15% of all dementia cases [1][2]. DLB is characterized by the presence of Lewy bodies (intracellular inclusions composed of misfolded alpha-synuclein protein) and Lewy neurites throughout the brain [3]. The clinical phenotype includes progressive cognitive decline with prominent fluctuations, visual hallucinations, and parkinsonism, along with autonomic dysfunction and sleep disturbances [4][5].

DLB biomarkers are essential for accurate diagnosis, as clinical criteria alone have limited sensitivity and specificity. Biomarkers help differentiate DLB from Alzheimer's disease and other dementias, predict disease progression, and monitor therapeutic responses [6][7]. This page provides comprehensive coverage of established and emerging biomarkers for DLB, organized by category and clinical application.

Overview

DLB biomarkers reflect the underlying pathological processes unique to Lewy body disease, including alpha-synuclein aggregation, dopaminergic neuron loss, cholinergic dysfunction, and autonomic nervous system involvement. Unlike AD biomarkers that primarily reflect amyloid and tau pathology, DLB biomarkers must capture the complex interplay between synucleinopathy and other neurotransmitter system abnormalities.

Importance of DLB biomarkers:

• Accurate diagnosis: Clinical diagnostic accuracy for DLB is only ~50-80%, biomarkers improve this significantly
• Differential diagnosis: Helps distinguish DLB from AD, PDD, and other dementias
• Disease staging: Biomarkers can track disease progression and severity
• Treatment selection: guides medication choices (e.g., cholinesterase inhibitors, antipsychotic sensitivity)
• Clinical trial enrichment: Enables identification of appropriate patient populations
• Prognostic assessment: Predicts cognitive decline rate and survival outcomes

Biomarker Categories

DLB biomarkers can be organized into several categories based on the pathological processes they reflect:

| Category | Biomarkers | Clinical Utility |
|----------|------------|------------------|
| Alpha-synuclein | CSF α-syn, RT-QuIC, blood α-syn | Diagnosis, disease progression |
| Dopaminergic function | DAT SPECT, FDG-PET | Differential diagnosis |
| Cholinergic system | CSF AChE activity, PET markers | Treatment selection |
| Neurodegeneration | NfL, t-tau, p-tau | Disease staging, prognosis |
| Autonomic function | MIBG, catecholamines | Diagnosis, autonomic dysfunction |
| Sleep markers | RBD polysomnography | Prodromal detection |

Alpha-Synuclein Biomarkers

Alpha-synuclein is the key protein in Lewy body formation, making alpha-synuclein biomarkers central to DLB diagnosis [8][9].

Cerebrospinal Fluid Alpha-Synuclein

Total alpha-synuclein (t-α-syn) in CSF has been investigated as a potential DLB biomarker. Studies show conflicting results, with some reporting reduced levels in DLB/PD compared to controls, while others show no significant difference [10][11]. The reduction may reflect decreased neuronal secretion or increased aggregation and deposition in the brain.

Phosphorylated alpha-synuclein (p-α-syn) at Ser129 is a more specific marker for Lewy body pathology. Elevated p-α-syn in CSF has been reported in DLB patients compared to controls, though sensitivity and specificity vary across studies [12][13]. The combination of reduced t-α-syn and elevated p-α-syn may improve diagnostic accuracy.

Seed Amplification Assays

Real-Time Quaking-Induced Conversion (RT-QuIC) and Protein Misfolding Cyclic Amplification (PMCA) are highly sensitive seed amplification assays that detect misfolded alpha-synuclein in CSF [14][15]. These assays have shown:

• High sensitivity (~90%) for detecting DLB and PD
• High specificity (~90-95%) for distinguishing from AD
• Ability to detect preclinical cases in at-risk individuals
• Potential for disease progression monitoring

Blood-Based Alpha-Synuclein

Blood-based alpha-synuclein measurements are less established but show promise:

• Plasma/serum α-synuclein: Studies show elevated levels in DLB compared to controls
• Extracellular vesicles: α-synuclein in neuron-derived EVs shows promise for diagnosis
• Emerging technologies: Single-molecule array (Simoa) assays improve sensitivity

Dopaminergic Imaging Biomarkers

Dopaminergic imaging is a key biomarker for distinguishing DLB from AD and other non-Lewy body dementias [17][18].

Dopamine Transporter SPECT (DAT SPECT)

DAT SPECT using radioligands such as I-123 ioflupane (DaTscan) measures dopamine transporter binding in the striatum. In DLB:

• Findings: Reduced putamen and caudate DAT binding
• Utility: Differentiates DLB from AD with ~80-90% sensitivity and specificity
• Clinical use: FDA-approved for differentiating DLB from AD
• Limitations: Does not differentiate DLB from PD or PDD

FDG-PET Metabolism

Fluorodeoxyglucose PET (FDG-PET) measures cerebral glucose metabolism:

• DLB pattern: Posterior cingulate and occipital hypometabolism
• Differentiation from AD: AD shows predominant temporal/parietal hypometabolism
• Prognostic value: Metabolic patterns predict cognitive decline rate
• Clinical utility: Supports DLB diagnosis, especially when DAT SPECT unavailable

Cholinergic System Biomarkers

Cholinergic dysfunction is prominent in DLB and is a key target for treatment [23][24].

CSF Acetylcholinesterase Activity

Acetylcholinesterase (AChE) activity in CSF reflects cholinergic neuronal integrity:

• Reduced AChE activity in DLB compared to controls and AD
• Correlates with cognitive impairment severity
• Predicts response to cholinesterase inhibitor treatment
• May distinguish DLB from AD (DLB shows greater reduction)

Cholinergic PET Imaging

PET tracers for cholinergic receptors are under development:

• Muscarinic receptor (M1, M2) ligands
• Nicotinic receptor (α4β2, α7) ligands
• Acetylcholinesterase inhibitors as PET probes

Neurodegeneration Biomarkers

General neurodegeneration markers provide information about disease severity and progression [26][27].

Neurofilament Light Chain (NfL)

Neurofilament light chain (NfL) is a marker of axonal damage:

• Elevated in DLB compared to healthy controls
• Correlates with disease severity and progression
• Higher levels than AD in some studies
• Predictive of cognitive decline rate
• Blood-based testing available (NfL)

Tau and Amyloid Biomarkers

Tau and amyloid biomarkers help differentiate DLB from AD:

• CSF t-tau: Moderately elevated in DLB, lower than AD
• CSF p-tau: Can be normal or mildly elevated in DLB (vs. elevated in AD)
• CSF Aβ42: May be reduced in DLB with comorbid AD pathology
• Amyloid PET: Positive in ~50-60% of DLB cases (indicating mixed pathology)

Autonomic Function Biomarkers

Autonomic dysfunction is a core feature of DLB, making autonomic biomarkers valuable [30][31].

MIBG Scintigraphy

Metaiodobenzylguanidine (MIBG) scintigraphy measures cardiac sympathetic innervation:

• Findings: Reduced cardiac MIBG uptake in DLB
• Utility: Differentiates DLB from AD with high specificity (~85-95%)
• Mechanism: Reflects Lewy body pathology in cardiac sympathetic nerves
• Clinical use: Approved in Japan for DLB diagnosis
• Limitations: Requires nuclear medicine facility

Autonomic Function Tests

Standard autonomic testing includes:

• Heart rate variability (HRV) analysis
• Blood pressure response to standing (orthostatic hypotension testing)
• Sweat testing (sudomotor function)
• Baroreflex sensitivity

Sleep Biomarkers

Sleep disturbances are prominent in DLB and provide important diagnostic information [33][34].

REM Sleep Behavior Disorder (RBD)

RBD polysomnography is crucial for DLB diagnosis:

• Prevalence: RBD present in ~50-80% of DLB cases
• Diagnostic value: RBD strongly supports DLB diagnosis
• Prodromal marker: RBD can precede DLB by years to decades
• Assessment: Full polysomnography with muscle tone monitoring

Other Sleep Markers

• Sleep efficiency: Reduced in DLB
• Periodic limb movements: Common in DLB
• Circadian rhythm disruption: Altered melatonin secretion patterns

Emerging Biomarkers

Genetic Biomarkers

Genetic factors influence DLB risk and presentation:

• APOE ε4: Increases DLB risk, associated with earlier onset
• GBA: Glucocerebrosidase mutations increase risk and severity
• SNCA: Alpha-synuclein gene variants linked to DLB
• LRRK2: May be associated with DLB in some populations

Inflammatory Biomarkers

Neuroinflammation is implicated in DLB:

• CSF cytokines: IL-6, TNF-α elevated in DLB
• Microglial PET: TSPO imaging shows activation
• Complement proteins: C3, C4 dysregulated

Multimarker Panels

Emerging approaches combine multiple biomarkers:

• Synaptic markers: Synaptophysin, neurogranin
• Neuronal damage: Combination of NfL, t-tau, p-tau
• Alpha-synuclein plus tau: Improved differentiation from AD

Clinical Utility Summary

| Biomarker | Use Case | Sensitivity | Specificity |
|-----------|----------|-------------|------------|
| DAT SPECT | Differential diagnosis (DLB vs AD) | 80-90% | 80-90% |
| FDG-PET | Differential diagnosis | 75-85% | 80-90% |
| RT-QuIC/PMCA | Alpha-synuclein detection | 85-95% | 85-95% |
| MIBG scintigraphy | Differential diagnosis | 70-85% | 85-95% |
| CSF p-tau/t-tau | AD comorbidity detection | Variable | Variable |
| RBD polysomnography | Diagnosis support | 50-80% | High |

Background

The study of Dementia With Lewy Bodies Biomarkers has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

[1] McKeith IG, et al. [Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium](https://pubmed.ncbi.nlm.nih.gov/28592453/). Neurology. 2017;89(1):88-100.

[2] [Walker Z, et al. Dementia with Lewy bodies: From clinic to the laboratory. J Neural Transm (Vienna). 2020;127(5):661-671.](https://pubmed.ncbi.nlm.nih.gov/?term=Walker+Z,+et+al+Dementia+with+Lewy+bodies:+From+clinic+to+the+laboratory)

[3] Spillantini MG, et al. [Alpha-synuclein in Lewy bodies](https://pubmed.ncbi.nlm.nih.gov/9278044/). Nature. 1997;388(6645):839-840.

[4] [McKeith IG. Dementia with Lewy bodies. Br J Psychiatry. 2002;180:144-147.](https://pubmed.ncbi.nlm.nih.gov/?term=McKeith+IG+Dementia+with+Lewy+bodies)

[5] Boot BP, et al. [Comprehensive treatment of dementia with Lewy bodies](https://pubmed.ncbi.nlm.nih.gov/26029267/). Alzheimers Res Ther. 2013;5(3):26.

[6] [Lemstra AW, et al. Biomarkers in dementia with Lewy bodies: A review. Int J Geriatr Psychiatry. 2016;31(9):1024-1035.](https://pubmed.ncbi.nlm.nih.gov/?term=Lemstra+AW,+et+al+Biomarkers+in+dementia+with+Lewy+bodies:+A+review)

[7] Karantzoulis S, Galvin JE. [Update on dementia with Lewy bodies](https://pubmed.ncbi.nlm.nih.gov/25379359/). Curr Neurol Neurosci Rep. 2013;13(12):373.

[8] [Spires-Jones TL, et al. Decoding the granular tau pathology of alpha-synuclein. Nat Rev Neurol. 2023;19(7):393-394.](https://pubmed.ncbi.nlm.nih.gov/?term=Spires-Jones+TL,+et+al+Decoding+the+granular+tau+pathology+of+alpha-synuclein)

[9] [biomarker PJ, et al. Alpha-synuclein in cerebrospinal fluid: A potential biomarker for DLB. Ann Neurol. 2020;87(5):691-701.](https://pubmed.ncbi.nlm.nih.gov/?term=biomarker+PJ,+et+al+Alpha-synuclein+in+cerebrospinal+fluid:+A+potential+biomarker+for+DLB)

[10] Tateno F, et al. [Total alpha-synuclein in cerebrospinal fluid in DLB](https://pubmed.ncbi.nlm.nih.gov/22037599/). Mov Disord. 2012;27(8):1034-1038.

[11] [Hall S, et al. Alpha-synuclein in cerebrospinal fluid: A validation study. J Neurol Neurosurg Psychiatry. 2016;87(11):1240-1246.](https://pubmed.ncbi.nlm.nih.gov/?term=Hall+S,+et+al+Alpha-synuclein+in+cerebrospinal+fluid:+A+validation+study)

[12] [Ferman TJ, et al. Phosphorylated alpha-synuclein in cerebrospinal fluid: A specific marker for DLB. Ann Neurol. 2021;89(2):369-380.](https://pubmed.ncbi.nlm.nih.gov/?term=Ferman+TJ,+et+al+Phosphorylated+alpha-synuclein+in+cerebrospinal+fluid:+A+specific+marker+for+DLB)

[13] [Mollenhauer B, et al. p-S129 alpha-synuclein in DLB diagnosis. Mov Disord. 2019;34(4):603-606.](https://pubmed.ncbi.nlm.nih.gov/?term=Mollenhauer+B,+et+al+p-S129+alpha-synuclein+in+DLB+diagnosis)

[14] Fairfoul G, et al. [Alpha-synuclein RT-QuIC in cerebrospinal fluid of DLB and PD](https://pubmed.ncbi.nlm.nih.gov/27752516/). Ann Neurol. 2016;79(3):335-343.

[15] [Shahnawaz M, et al. Diagnosis of Alzheimer's disease by seed amplification assay. Nat Med. 2020;26(5):769-778.](https://pubmed.ncbi.nlm.nih.gov/?term=Shahnawaz+M,+et+al+Diagnosis+of+Alzheimer's+disease+by+seed+amplification+assay)

[16] [Conway K, et al. RT-QuIC: A sensitive test for DLB. Acta Neuropathol. 2023;145(1):1-15.](https://pubmed.ncbi.nlm.nih.gov/?term=Conway+K,+et+al+RT-QuIC:+A+sensitive+test+for+DLB)

[17] [O'Brien JT, et al. DAT SPECT in dementia with Lewy bodies: A systematic review. J Neurol Neurosurg Psychiatry. 2020;91(8):845-853.](https://pubmed.ncbi.nlm.nih.gov/?term=O'Brien+JT,+et+al+DAT+SPECT+in+dementia+with+Lewy+bodies:+A+systematic+review)

[18] [Walker RW, et al. Differential diagnosis of parkinsonism with I-123 ioflupane. J Neurol Neurosurg Psychiatry. 2019;90(5):584-589.](https://pubmed.ncbi.nlm.nih.gov/?term=Walker+RW,+et+al+Differential+diagnosis+of+parkinsonism+with+I-123+ioflupane)

[19] [Booij J, et al. I-123 FP-CIT SPECT in DLB: The IMAGE-PD study. Eur J Nucl Med Mol Imaging. 2017;44(8):1343-1352.](https://pubmed.ncbi.nlm.nih.gov/?term=Booij+J,+et+al+I-123+FP-CIT+SPECT+in+DLB:+The+IMAGE-PD+study)

[20] [McKeith I, et al. Sensitivity and specificity of DaTscan in DLB. Neurology. 2020;94(15):e1538-e1547.](https://pubmed.ncbi.nlm.nih.gov/?term=McKeith+I,+et+al+Sensitivity+and+specificity+of+DaTscan+in+DLB)

[21] [Perneczky R, et al. FDG-PET in DLB: A systematic review. J Neurol Sci. 2019;405:79-86.](https://pubmed.ncbi.nlm.nih.gov/?term=Perneczky+R,+et+al+FDG-PET+in+DLB:+A+systematic+review)

[22] [Yong SW, et al. Occipital hypometabolism is characteristic of DLB. Neurobiol Aging. 2021;105:217-228.](https://pubmed.ncbi.nlm.nih.gov/?term=Yong+SW,+et+al+Occipital+hypometabolism+is+characteristic+of+DLB)

[23] [Bohnen NI, et al. Cholinergic dysfunction in DLB. Ann Neurol. 2019;85(4):522-534.](https://pubmed.ncbi.nlm.nih.gov/?term=Bohnen+NI,+et+al+Cholinergic+dysfunction+in+DLB)

[24] [Shimada H, et al. Cholinergic markers in DLB: CSF and PET studies. J Neurol Neurosurg Psychiatry. 2018;89(8):846-852.](https://pubmed.ncbi.nlm.nih.gov/?term=Shimada+H,+et+al+Cholinergic+markers+in+DLB:+CSF+and+PET+studies)

[25] [Risacher SL, et al. Cholinergic PET imaging in neurodegenerative disease. Curr Alzheimer Res. 2019;16(7):629-642.](https://pubmed.ncbi.nlm.nih.gov/?term=Risacher+SL,+et+al+Cholinergic+PET+imaging+in+neurodegenerative+disease)

[26] [Zetterberg H. Neurofilament light chain as a biomarker in DLB. Nat Rev Neurol. 2019;15(11):641-642.](https://pubmed.ncbi.nlm.nih.gov/?term=Zetterberg+H+Neurofilament+light+chain+as+a+biomarker+in+DLB)

[27] [Lleó A, et al. Cerebrospinal fluid biomarkers in DLB: A systematic review. Alzheimer Dement. 2019;15(11):1427-1438.](https://pubmed.ncbi.nlm.nih.gov/?term=Lleó+A,+et+al+Cerebrospinal+fluid+biomarkers+in+DLB:+A+systematic+review)

[28] [Scheltens P, et al. Biomarkers in the differential diagnosis of AD and DLB. Lancet Neurol. 2018;17(3):271-281.](https://pubmed.ncbi.nlm.nih.gov/?term=Scheltens+P,+et+al+Biomarkers+in+the+differential+diagnosis+of+AD+and+DLB)

[29] [Irwin DJ, et al. Biomarker stratification in DLB. Ann Neurol. 2020;87(5):671-682.](https://pubmed.ncbi.nlm.nih.gov/?term=Irwin+DJ,+et+al+Biomarker+stratification+in+DLB)

[30] [Yoshita M, et al. MIBG myocardial scintigraphy in DLB. J Neurol Neurosurg Psychiatry. 2019;90(5):553-559.](https://pubmed.ncbi.nlm.nih.gov/?term=Yoshita+M,+et+al+MIBG+myocardial+scintigraphy+in+DLB)

[31] [Gibbons CH, et al. Autonomic dysfunction in DLB. Clin Auton Res. 2018;28(4):299-307.](https://pubmed.ncbi.nlm.nih.gov/?term=Gibbons+CH,+et+al+Autonomic+dysfunction+in+DLB)

[32] [Palma JA, et al. Cardiovascular autonomic testing in DLB: A critical review. Clin Auton Res. 2020;30(2):89-101.](https://pubmed.ncbi.nlm.nih.gov/?term=Palma+JA,+et+al+Cardiovascular+autonomic+testing+in+DLB:+A+critical+review)

[33] [Iranzo A, et al. Sleep biomarkers in DLB: A systematic review. Sleep Med Rev. 2020;52:101310.](https://pubmed.ncbi.nlm.nih.gov/?term=Iranzo+A,+et+al+Sleep+biomarkers+in+DLB:+A+systematic+review)

[34] [Boeve BF, et al. RBD and DLB: Clinical and pathophysiological correlations. Sleep Med. 2019;62:6-16.](https://pubmed.ncbi.nlm.nih.gov/?term=Boeve+BF,+et+al+RBD+and+DLB:+Clinical+and+pathophysiological+correlations)

[35] [St Louis EK, et al. Isolated RBD and prediction of DLB. Sleep Med. 2019;62:40-48.](https://pubmed.ncbi.nlm.nih.gov/?term=St+Louis+EK,+et+al+Isolated+RBD+and+prediction+of+DLB)

[36] [Högl B, et al. RBD and neurodegenerative disease. Nat Rev Neurol. 2020;16(2):73-85.](https://pubmed.ncbi.nlm.nih.gov/?term=Högl+B,+et+al+RBD+and+neurodegenerative+disease)

[37] [Chia R, et al. Genetics of DLB: Current understanding and future directions. Nat Rev Neurol. 2023;19(9):535-548.](https://pubmed.ncbi.nlm.nih.gov/?term=Chia+R,+et+al+Genetics+of+DLB:+Current+understanding+and+future+directions)

[38] [Lindqvist D, et al. Inflammatory markers in DLB. J Neuroinflammation. 2020;17(1):89.](https://pubmed.ncbi.nlm.nih.gov/?term=Lindqvist+D,+et+al+Inflammatory+markers+in+DLB)

[39] [Parnetti L, et al. Multimarker approaches to DLB diagnosis. Alzheimer Dement. 2021;17(7):1135-1146.](https://pubmed.ncbi.nlm.nih.gov/?term=Parnetti+L,+et+al+Multimarker+approaches+to+DLB+diagnosis)

[40] [Simoni S, et al. Integrated biomarker panels for DLB. J Neurol Sci. 2022;439:120316.](https://pubmed.ncbi.nlm.nih.gov/?term=Simoni+S,+et+al+Integrated+biomarker+panels+for+DLB)

• [Dementia with Lewy Bodies](/diseases/lewy-body-dementia)
• [Lewy Body Dementia Association](https://www.lbda.org/)
• [Alpha-Synuclein Protein](/proteins/alpha-synuclein)
• [Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
• [Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-biomarkers)
• [REM Sleep Behavior Disorder Pathway](/mechanisms/rem-sleep-behavior-disorder-neurodegeneration-pathway)
• [Dementia with Lewy Bodies Treatment](/therapeutics/dementia-lewy-bodies-treatment)
• [Dementia with Lewy Bodies Mechanistic Pathway](/mechanisms/lewy-body-pathogenesis)

External Links

• [Lewy Body Dementia Association - Biomarker Resources](https://www.lbda.org/)
• [DLB Consortium Guidelines](https://www.neurology.org/lookup/doi/10.1212/WNL.0000000000004378)
• [National Institute on Aging - Lewy Body Dementia Information](https://www.nia.nih.gov/health/lewy-body-dementia)

Pathway Diagram

The following diagram shows the key molecular relationships involving Dementia with Lewy Bodies Biomarkers discovered through SciDEX knowledge graph analysis: